The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- CMS Coverage With Evidence Development Guidance: Update Says CED Could Become More Frequent With Earlier Stage Technologies Nov. 20, 2014
- Generic Medicaid Rebate Increase Proposed By Senate Democrats; GOP Response Reaffirms Pricing Flexibility In New Political Climate Nov. 20, 2014
- FDA Prepares Anti-Infective Drugs Advisory Committee For Historic Meeting: Less Data For Unmet Needs Is Focus Nov. 20, 2014
See More Research Notes